Papillorenal syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Esther Lee (talk | contribs) (Created page with "__NOTOC__ {{Papillorenal syndrome}} {{CMG}} ==Overview== ==Secondary Prevention== Management of the disease should be focused on preventing end-stage renal disease (ESRD) an...") |
No edit summary |
||
| Line 16: | Line 16: | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Syndromes]] | [[Category:Syndromes]] | ||
[[Category: | [[Category:Needs content]] | ||
[[Category:Disease]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 14:03, 28 September 2012
|
Papillorenal syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Papillorenal syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Papillorenal syndrome secondary prevention |
|
Risk calculators and risk factors for Papillorenal syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Secondary Prevention
Management of the disease should be focused on preventing end-stage renal disease (ESRD) and/or vision loss. The treatment of hypertension may also preserve renal function. Renal replacement therapy is recommended, and vision experts may provide assistance to adapt to continued vision loss.[1]